Drug Trial Radar · NCT07585266
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Aug 30, 2032
Study completion Sep 28, 2032
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cause the cells to grow uncontrollably. Although current treatments may be effective, tumours may stop responding over time, highlighting the need for newer options. This study is evaluating velzatinib (GSK6042981) in participants with newly diagnosed GIST that has spread or cannot be surgically removed. Velzatinib will be compared with imatinib, the standard treatment, to assess whether it can delay disease worsening and is safe and well tolerated.
Conditions
- Gastrointestinal Stromal Neoplasms
Interventions
VelzatinibDrug
Velzatinib will be administered
ImatinibDrug
Imatinib will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as assessed by Blinded independent central review (BICR)Time frame: Up to approximately 74 months
Locations
93 sites in 20 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Scottsdale, Arizona · Recruiting
GSK Investigational Site
San Francisco, California · Recruiting
GSK Investigational Site
New Haven, Connecticut · Recruiting
GSK Investigational Site
Bethesda, Maryland · Recruiting
GSK Investigational Site
Kansas City, Missouri · Recruiting
GSK Investigational Site
Omaha, Nebraska · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
Durham, North Carolina · Recruiting
GSK Investigational Site
Canton, Ohio · Recruiting
GSK Investigational Site
Knoxville, Tennessee · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Seattle, Washington · Recruiting
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Capital Federal, Argentina · Recruiting
GSK Investigational Site
Ciudad autOnoma de Bueno, Argentina · Recruiting
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina · Recruiting
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina · Recruiting
GSK Investigational Site
San Miguel de Tucumán, Argentina · Recruiting
GSK Investigational Site
Melbourne, Victoria, Australia · Recruiting
GSK Investigational Site
Barretos, Brazil · Recruiting
GSK Investigational Site
Florianópolis, Brazil · Recruiting
GSK Investigational Site
Natal, Brazil · Recruiting
GSK Investigational Site
Porto Alegre, Brazil · Recruiting
GSK Investigational Site
Vitória, Brazil · Recruiting
GSK Investigational Site
Teresina, Piauí, Brazil · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Beijing, China · Recruiting
GSK Investigational Site
Chengdu, China · Recruiting
GSK Investigational Site
Guangzhou, China · Recruiting
GSK Investigational Site
Guangzhou, China · Recruiting
GSK Investigational Site
Guangzhou, China · Recruiting
GSK Investigational Site
Hangzhou, China · Recruiting
GSK Investigational Site
Jinan, China · Recruiting
GSK Investigational Site
Nanjing, China · Recruiting
GSK Investigational Site
Shanghai, China · Recruiting
GSK Investigational Site
Shanghai, China · Recruiting
GSK Investigational Site
Wuhan, China · Recruiting
GSK Investigational Site
Zhengzhou, China · Recruiting
GSK Investigational Site
Helsinki, Finland · Recruiting
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.